Table 2.
Second-line treatment in non-responders to eradication therapy in gastric MALT lymphoma.
| n | Stage | HP (−) | Non-CR, n (%) |
2nd-Tx | 2nd-Tx * | Ref. | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WW | RT | Other Tx | |||||||||||
| n | CR Rate |
n | CR Rate |
n | CR Rate |
n | CR Rate | ||||||
| 105 | I, II1 | 13% | 24 | (24%) | 10 | NE | 14 (CTx ± IM 12, CTx + S 1, S 1) | 27% | [27] | ||||
| 60 | I, II1 | 12% | 10 | (17%) | 1 | 0% (SD 1) | 7 | 100% | 2 (RT + CTx 1, ER 1) | 100% | [26] | ||
| 420 | I–IV | 10% | 97 | (23%) | 15 | 0% (NC 15) | 82 † | 94% | [7] | ||||
| 66 | I, II1 | 20% | 16 | (29%) | 2 | 50% | 9 | 89% | 1 (CTx) | 0% | [24] | ||
| 345 | I–IV | 8% | 61 | (18%) | 42 | NE | 17 | 88% | 1 (CTx) | 100% | [8] | ||
| 339 | I–IV | 40% | 157 | (61%) | 57 | NE | 100 ‡ | 79% | [9] | ||||
| 96 | I–IV | 39% | 44 | (60%) | 3 | NE | 33 | 91% | 5 (CTx) | 63% | [28] | ||
CR: complete remission; CTx: chemotherapy; ER: endoscopic resection; HP: Helicobacter pylori; IM: immunotherapy; NC: no change; NE: no evaluation; R: rituximab; RT: radiotherapy; S: surgery; SD: stable disease; Tx: treatment; WW: watch and wait. * CR rate of each treatment was unavailable. † RT 47, CTx 22, RT + CTx 5, S 5, ER 1, R 1, and third-line antibiotic therapy 1; ‡ RT, CTx ± IM, and Sur were performed but detailed information was unavailable.